In a report issued on October 12, Liisa Bayko from JMP Securities maintained a Buy rating on Heron Therapeutics (NASDAQ: HRTX), with a price target of $50. The company’s shares closed yesterday at $29.14.
According to TipRanks.com, Bayko is a 5-star analyst with an average return of 19.7% and a 47.6% success rate. Bayko covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, DBV Technologies SA – American, and Arbutus Biopharma Corporation.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Heron Therapeutics with a $50 average price target, representing a 71.6% upside. In a report issued on September 27, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $30 price target.
.
See today’s analyst top recommended stocks >>
Based on Heron Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $38.67 million. In comparison, last year the company had a GAAP net loss of $41.87 million.
Based on the recent corporate insider activity of 16 insiders, corporate insider sentiment is neutral on the stock. Last month, Barry Quart, the CEO of HRTX bought 19,675 shares for a total of $141,660.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Heron Therapeutics, Inc. is a biotechnology company, which develops pharmaceutical products for patients suffering from cancer. The company develops products by using its proprietary Biochronomer polymer based drug delivery technology. Its products include SUSTOL, Pipeline, Cinvanti and HTX-011.
